Hester Biosciences Limited (NSE: HESTERBIO) disclosed two significant developments on October 6, 2026: its board approved an investment in a Limited Liability Partnership for Group Captive Power Generation, while the company's dividend history reveals a sharply improved payout trajectory, with the FY26 final dividend of ₹11 per equity share representing a 57.1% increase over the ₹7 per share declared for FY25.

Board Approves Captive Power Investment

The board meeting held on October 6, 2026 resulted in a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming Hester Biosciences' investment in an LLP structured for Group Captive Power Generation. Captive power arrangements typically allow companies to source electricity at below-market tariffs by collectively owning generation capacity, which can meaningfully reduce input costs for manufacturing-intensive pharmaceutical and veterinary biologicals businesses. The financial size of the LLP investment was not disclosed in the exchange filing.

Dividend Details and Year-on-Year Comparison

The FY26 final dividend of ₹11 per equity share was recommended by the board on May 15, 2026. This compares to ₹7 per share in FY25, ₹6 per share in FY24, and ₹8 per share in FY23. Since quote and trade data are unavailable at the time of this report, a precise dividend yield cannot be calculated. Investors should compute yield against the prevailing market price on the record date once it is announced by the company.

Dividend History: A Decade-Long Trend

Hester Biosciences has maintained an unbroken dividend payout record over the past seven financial years. The full payout sequence is as follows:

The FY26 payout of ₹11 per share is the highest in this eight-year recorded history, surpassing the previous peak of ₹10 per share paid in both FY21 and FY22. The dip to ₹6 in FY24 followed by a recovery to ₹7 in FY25 and then a sharp rise to ₹11 in FY26 suggests that earnings momentum has meaningfully accelerated in the most recent financial year.

Company Background

Hester Biosciences is an Ahmedabad-based manufacturer of veterinary vaccines and health products, with operations spanning poultry vaccines, large animal biologicals, and animal health formulations. The company also has an international presence through subsidiaries in Nepal and Africa. Its manufacturing facilities are approved by regulatory bodies including USDA and OIE-certified laboratories, positioning it in a niche but growing segment of animal healthcare in India and emerging markets.

What This Means for Investors

The 57% jump in dividend per share from FY25 to FY26 signals strong free cash flow generation in the latest fiscal year. The captive power LLP investment, if structured efficiently, could lower energy costs and support operating margin improvement in future periods. Investors tracking the stock should note the record date for the FY26 dividend, which has not yet been announced, as eligibility for the ₹11 per share payout is contingent on holding shares on that date. The consistency of annual payouts since at least FY19 underscores a management policy that prioritizes regular shareholder returns alongside reinvestment in infrastructure.